21:28 , Jul 19, 2019 |  BC Extra  |  Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

Samumed's Alzheimer's candidate reduces tau pathology, inflammation  Samumed LLC (San Diego, Calif.) reported in an Aging Cell paper that SM07883 reduced tau phosphorylation, pathological tau aggregates, neuroinflammation, weight loss and mortality in a mouse model...
01:01 , May 7, 2019 |  BC Innovations  |  Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Gene expression profiling in neurons, oligodendrocytes, microglia and other CNS cell types could help diagnose early Alzheimer's disease. In post-mortem prefrontal cortex samples AD patient and unaffected...
16:59 , Jan 12, 2018 |  BC Week In Review  |  Company News

ProQR, Galapagos in oligonucleotide deal for fibrosis

ProQR Therapeutics N.V. (NASDAQ:PRQR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) partnered to discover Axiomer Editing Oligonucleotides (EONs) against Galapagos' fibrosis targets using ProQR's Axiomer RNA technology. Deal terms were not disclosed. ProQR's EONs mediate single nucleotide...
12:38 , Jan 8, 2018 |  BC Extra  |  Company News

ProQR, Galapagos in oligonucleotide deal for fibrosis

ProQR Therapeutics N.V. (NASDAQ:PRQR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) partnered to discover Axiomer Editing Oligonucleotides (EONs) against Galapagos' fibrosis targets using ProQR's Axiomer RNA technology. Deal terms were not disclosed. ProQR's EONs mediate single nucleotide...
18:08 , Dec 20, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy An ADARB2-based method of editing RNA could help treat diseases caused by point mutations, such as Rett syndrome and X-linked nephrogenic diabetes insipidus. The method repairs disease-associated G to A mutations in...
07:00 , Mar 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-455-5p (miR-455-5p); adenosine deaminase RNA-specific (ADAR; ADAR1)

Cancer INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting wild-type miR-455-5p or stimulating ADAR1 activity could help prevent metastatic melanoma. In normal cells, the RNA-editing enzyme ADAR1 converts adenosine to inosine at two positions...
08:00 , Nov 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) Chromosome 9 open reading frame 72 (C9orf72) Studies in patient samples and mice suggest antisense oligonucleotides targeting...
08:00 , Nov 7, 2013 |  BC Innovations  |  Cover Story

ALS antisense oligonucleotides

Isis Pharmaceuticals Inc. has teamed up with a trio of academic groups to develop antisense therapeutics for the largest subset of patients with amyotrophic lateral sclerosis, 1-3 and all three teams have converged on a...
08:00 , Feb 10, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Phosphatidylserine-displaying liposomes to decrease inflammation Liposomes engineered to display phosphatidylserine on their surface could be used to repair tissue damage after heart attacks. In a...